Publicaciones (40) Publicaciones de Iciar Avilés Olmos

2024

  1. Agrypnia Excitata and Supranuclear Vertical Gaze Palsy Linked to Anti-Ma Encephalitis

    Movement Disorders Clinical Practice, Vol. 11, Núm. 5, pp. 571-574

  2. Magnetic Resonance-Guided Focused Ultrasound (MRgFUS)-Thalamotomy for Essential Tremor: Lesion Location and Clinical Outcomes

    Movement Disorders

2023

  1. Towards an adiposity-related disease framework for the diagnosis and management of obesities

    Reviews in Endocrine and Metabolic Disorders, Vol. 24, Núm. 5, pp. 795-807

2022

  1. Time to Consider the “Exposome Hypothesis” in the Development of the Obesity Pandemic

    Nutrients, Vol. 14, Núm. 8

2021

  1. Factors Associated with Headache and Nausea During Magnetic Resonance–Guided Focused Ultrasound for Tremor

    Movement Disorders Clinical Practice, Vol. 8, Núm. 5, pp. 701-708

  2. Pedunculopontine Nucleus Deep Brain Stimulation for Parkinsonian Disorders: A Case Series

    Stereotactic and Functional Neurosurgery, Vol. 99, Núm. 4, pp. 287-294

2019

  1. Post hoc analysis of the Exenatide-PD trial—Factors that predict response

    European Journal of Neuroscience, Vol. 49, Núm. 3, pp. 410-421

2018

  1. Incobotulinumtoxin a for sialorrhea in neurological disorders: A real-life experience

    Toxins, Vol. 10, Núm. 6

  2. Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients

    Parkinsonism and Related Disorders, Vol. 52, pp. 83-89

  3. What effects might exenatide have on non-motor symptoms in Parkinson's disease: A post Hoc analysis

    Journal of Parkinson's Disease, Vol. 8, Núm. 2, pp. 247-258

2017

  1. Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration

    Movement Disorders Clinical Practice, Vol. 4, Núm. 4, pp. 536-544

  2. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial

    The Lancet, Vol. 390, Núm. 10103, pp. 1664-1675

  3. Thalamic-Caudal Zona Incerta Deep Brain Stimulation for Refractory Orthostatic Tremor: A Report of 3 Cases

    Movement Disorders Clinical Practice, Vol. 4, Núm. 1, pp. 105-110

2016

  1. A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease

    Science Translational Medicine, Vol. 8, Núm. 341

  2. Comunicación clínica para neurólogos: eficacia, enseñanza y situaciones clínicas en pacientes con enfermedad de Parkinson

    Editorial UFV

  3. Quantitative gait analysis in patients with advanced parkinson’s disease

    Revista de Neurologia, Vol. 63, Núm. 3, pp. 97-102

  4. Therapeutic advances in Huntington’s disease

    Expert Opinion on Orphan Drugs, Vol. 4, Núm. 8, pp. 809-821

2015

  1. Motor and Cognitive Advantages Persist 12 Months after Exenatide Exposure in Parkinson's Disease

    Journal of Parkinson's Disease, Vol. 4, Núm. 3, pp. 337-344

2014

  1. Exenatide as a potential treatment for patients with Parkinson's disease: First steps into the clinic

    Alzheimer's and Dementia, Vol. 10, Núm. 1 SUPPL.

  2. In a rush to decide: Deep brain stimulation and dopamine agonist therapy in Parkinson's disease

    Journal of Parkinson's Disease, Vol. 4, Núm. 4, pp. 579-583